Related Experiment Video
Updated: Jan 24, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Anticoagulation Resumption After Stroke from Atrial Fibrillation
Brian Mac Grory1, Shane Flood2, Matthew Schrag3
1Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Resuming anticoagulation after stroke from atrial fibrillation requires balancing recurrent stroke risk against hemorrhagic transformation. Current research limitations highlight the need for personalized treatment strategies based on individual patient factors.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation increases stroke risk, necessitating anticoagulation.
- Ischemic stroke carries a risk of recurrent stroke and hemorrhagic transformation, especially in the early post-stroke period.
- Early anticoagulation resumption after stroke is complex due to competing risks.
Purpose of the Study:
- To review existing literature on anticoagulation resumption timing after stroke in atrial fibrillation patients.
- To identify challenges and limitations in current research regarding anticoagulation resumption protocols.
- To emphasize the need for personalized treatment decisions balancing risks.
Main Methods:
- Literature review of studies on anticoagulation resumption after ischemic stroke.
- Analysis of risks associated with recurrent stroke and hemorrhagic transformation.
- Examination of ongoing clinical trials comparing anticoagulant resumption protocols.
Main Results:
- Oral anticoagulants significantly reduce the relative risk of recurrent stroke.
- The early post-stroke period (2 weeks) presents elevated risks of both recurrent stroke and hemorrhagic transformation.
- Existing studies have limitations in accounting for crucial patient-specific factors like infarct size and bleeding diatheses.
Conclusions:
- The decision to resume anticoagulation requires a careful balance between preventing recurrent stroke and avoiding hemorrhagic transformation.
- Personalized treatment strategies are crucial, considering individual patient factors not fully addressed in current research.
- Ongoing trials aim to refine anticoagulant resumption protocols, particularly for non-vitamin K oral anticoagulant users.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...

